NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy
https://www.brainwork.md/content/uploads/2017/10/Brainwork-NavigateESUS.jpg 2992 2000 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=gEarly discontinuation has been announced for the Phase III NAVIGATE ESUS study – led by Bayer AG and its development partner Janssen Research & Development,…
read more